Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab.

Jung CW, Cho SH, Park S, Jang JH, Ji JH.

Blood Res. 2016 Dec;51(4):297-299. doi: 10.5045/br.2016.51.4.297. No abstract available.

2.

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis.

Wang L, Gao Z, Chen XP, Zhang HY, Yang N, Wang FY, Guan LX, Gu ZY, Zhao SS, Luo L, Wei HP, Gao CJ.

Sci Rep. 2016 Dec 19;6:39003. doi: 10.1038/srep39003.

3.
4.

Eltrombopag for the treatment of aplastic anemia: current perspectives.

Lum SH, Grainger JD.

Drug Des Devel Ther. 2016 Sep 13;10:2833-2843. Review.

5.

Advances in Diagnosis and Treatments for Immune Thrombocytopenia.

Nomura S.

Clin Med Insights Blood Disord. 2016 Jul 17;9:15-22. doi: 10.4137/CMBD.S39643. Review.

7.
8.

Severe Thrombotic Complication of Eltrombopag in a Cirrhotic Patient.

Baumann AJ, Wheeler DS, Varadi G, Feyssa E.

ACG Case Rep J. 2016 Jan 20;3(2):121-3. doi: 10.14309/crj.2016.20.

9.

Development and validation of a LC-MS/MS method for quantification of hetrombopag for pharmacokinetics study.

Chen T, Chen Z, Zhang S, Zhang K, Wang L.

Springerplus. 2015 Oct 29;4:652. doi: 10.1186/s40064-015-1446-0.

10.

Current Management of Primary Immune Thrombocytopenia.

Provan D, Newland AC.

Adv Ther. 2015 Oct;32(10):875-87. doi: 10.1007/s12325-015-0251-z. Review.

11.

Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Vaughn JE, Anwer F, Deeg HJ.

Vox Sang. 2016 Jan;110(1):5-11. doi: 10.1111/vox.12314. Review.

12.

Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival.

Kalota A, Selak MA, Garcia-Cid LA, Carroll M.

PLoS One. 2015 Apr 27;10(4):e0126691. doi: 10.1371/journal.pone.0126691.

13.

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.

Özdemirkıran F, Payzın B, Kiper HD, Kabukçu S, Akgün Çağlıyan G, Kahraman S, Sevindik ÖG, Ceylan C, Kadıköylü G, Şahin F, Keskin A, Arslan Ö, Özcan MA, Kabukçu G, Görgün G, Bolaman Z, Büyükkeçeci F, Bilgir O, Alacacıoğlu İ, Vural F, Tombuloğlu M, Gökgöz Z, Saydam G.

Turk J Haematol. 2015 Dec;32(4):323-8. doi: 10.4274/tjh.2014.0152.

14.

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.

Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ.

Blood Res. 2015 Mar;50(1):19-25. doi: 10.5045/br.2015.50.1.19.

15.

Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia.

Arnold DM, Nazi I, Toltl LJ, Ross C, Ivetic N, Smith JW, Liu Y, Kelton JG.

Eur J Haematol. 2015 Dec;95(6):532-7. doi: 10.1111/ejh.12528.

16.

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM.

J Thromb Haemost. 2015 Mar;13(3):457-64. doi: 10.1111/jth.12813. Review.

17.

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.

Danish FI, Yasmin S.

Hepat Med. 2013 Mar 15;5:17-30. doi: 10.2147/HMER.S27100. Review.

18.

Novel treatments for immune thrombocytopenia.

Shih A, Nazi I, Kelton JG, Arnold DM.

Presse Med. 2014 Apr;43(4 Pt 2):e87-95. doi: 10.1016/j.lpm.2014.02.006. Review.

19.

Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.

Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB.

Haematologica. 2014 May;99(5):937-44. doi: 10.3324/haematol.2013.098921.

20.

Clinical indications for thrombopoietin and thrombopoietin-receptor agonists.

Wörmann B.

Transfus Med Hemother. 2013 Oct;40(5):319-25. doi: 10.1159/000355006. Review.

Items per page

Supplemental Content

Support Center